JP2023545432A5 - - Google Patents
Info
- Publication number
- JP2023545432A5 JP2023545432A5 JP2023521682A JP2023521682A JP2023545432A5 JP 2023545432 A5 JP2023545432 A5 JP 2023545432A5 JP 2023521682 A JP2023521682 A JP 2023521682A JP 2023521682 A JP2023521682 A JP 2023521682A JP 2023545432 A5 JP2023545432 A5 JP 2023545432A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- product according
- pharmaceutical product
- approximately
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063090272P | 2020-10-11 | 2020-10-11 | |
| US63/090,272 | 2020-10-11 | ||
| US202163148038P | 2021-02-10 | 2021-02-10 | |
| US63/148,038 | 2021-02-10 | ||
| US202163193493P | 2021-05-26 | 2021-05-26 | |
| US63/193,493 | 2021-05-26 | ||
| PCT/US2021/054084 WO2022076767A1 (en) | 2020-10-11 | 2021-10-08 | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545432A JP2023545432A (ja) | 2023-10-30 |
| JP2023545432A5 true JP2023545432A5 (https=) | 2024-10-11 |
Family
ID=81125466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521682A Pending JP2023545432A (ja) | 2020-10-11 | 2021-10-08 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）を用いたがんの治療のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230364254A1 (https=) |
| EP (1) | EP4225379A4 (https=) |
| JP (1) | JP2023545432A (https=) |
| KR (1) | KR20230106607A (https=) |
| AU (1) | AU2021356542A1 (https=) |
| CA (1) | CA3198359A1 (https=) |
| IL (1) | IL302006A (https=) |
| MX (1) | MX2023004089A (https=) |
| TW (1) | TW202228788A (https=) |
| WO (1) | WO2022076767A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019392090A1 (en) | 2018-12-03 | 2021-06-17 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| WO2024012541A1 (zh) * | 2022-07-14 | 2024-01-18 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体药物偶联物及应用 |
| WO2024012536A1 (zh) * | 2022-07-14 | 2024-01-18 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体、其抗体药物偶联物及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX347954B (es) * | 2010-09-29 | 2017-05-19 | Agensys Inc | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. |
| AU2019342099A1 (en) * | 2018-09-19 | 2021-04-08 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
| AU2019392090A1 (en) * | 2018-12-03 | 2021-06-17 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| AU2020241963A1 (en) * | 2019-03-17 | 2021-11-04 | Vasgene Therapeutics Inc | Treatment of cancers using sEphB4-HSA fusion proteins |
| TW202540197A (zh) * | 2019-08-13 | 2025-10-16 | 美商艾澤西公司 | 以結合191p4d12蛋白質之抗體藥物結合物(adc)治療癌症 |
| KR20230091885A (ko) * | 2020-09-17 | 2023-06-23 | 어젠시스 인코포레이티드 | 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)로 암을 치료하는 방법 |
-
2021
- 2021-10-08 IL IL302006A patent/IL302006A/en unknown
- 2021-10-08 WO PCT/US2021/054084 patent/WO2022076767A1/en not_active Ceased
- 2021-10-08 US US18/030,225 patent/US20230364254A1/en active Pending
- 2021-10-08 CA CA3198359A patent/CA3198359A1/en active Pending
- 2021-10-08 KR KR1020237015737A patent/KR20230106607A/ko active Pending
- 2021-10-08 MX MX2023004089A patent/MX2023004089A/es unknown
- 2021-10-08 TW TW110137596A patent/TW202228788A/zh unknown
- 2021-10-08 JP JP2023521682A patent/JP2023545432A/ja active Pending
- 2021-10-08 EP EP21878582.2A patent/EP4225379A4/en active Pending
- 2021-10-08 AU AU2021356542A patent/AU2021356542A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240325530A1 (en) | Combination therapies | |
| JP2023545432A5 (https=) | ||
| WO2019096194A1 (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2009533456A (ja) | 眼疾患処置のためのｉｌ−１抗体の使用 | |
| US10792370B2 (en) | Antibody-drug conjugate | |
| TW201249460A (en) | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of B-cell malignancies symptoms | |
| CA3118777A1 (en) | Methods of treating graves' ophthalmopathy using anti-fcrn antibodies | |
| JP2023542879A5 (https=) | ||
| JP2024133544A5 (https=) | ||
| JP2025501978A5 (https=) | ||
| JP2022513684A5 (https=) | ||
| JP2021518394A5 (https=) | ||
| JP2022513386A5 (https=) | ||
| JP2021523233A5 (https=) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| WO2018005967A1 (en) | Compositions for treating amyloidosis | |
| JP2023500697A5 (https=) | ||
| KR20200010472A (ko) | 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임 | |
| CN102834413A (zh) | 代谢障碍的治疗 | |
| JP2024534012A5 (https=) | ||
| EP4577301A1 (en) | Actrii antibody fixed unit dose treatments | |
| WO2011090005A1 (ja) | 大腸癌の治療用医薬および治療方法 | |
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| WO2021060425A1 (ja) | 全身性強皮症治療用医薬組成物 | |
| WO2024183622A1 (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 |